ABA Chemicals Corporation Class A

ABA Chemicals Corporation Class A

SSZSE:300261
4.14
CNY
-0.06
(-1.43%)
-0.45EPS
4.74BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.54
0.89
0.81
0.83
1.41
1.87
1.73
2.09
2.17
2.1
1.34
1.26
1.37
1.1
Basic EPS, GAAP
0.06
0.09
0.08
0.02
0.09
0.17
0.08
0.17
0.19
0.21
-0.09
-0.27
-0.17
-0.44
Free Cash Flow per Basic Share
-0.16
-0.46
-0.12
-0.1
0.13
- -
-0.01
0.26
0.35
-0.11
-0.27
0.06
-0.13
- -
Dividend per Share
0.04
0.05
0.05
0.03
0.05
0.12
0.14
0.1
0.09
0.04
0.08
0.09
0.04
0.05
Book Value per Share
0.83
0.88
0.94
1.26
1.98
2.06
2.05
2.13
2.26
2.48
2.36
2.08
1.95
1.63
Tangible Book Value per Share
0.79
0.8
0.87
1.03
1.71
1.48
1.47
1.54
1.69
1.88
1.76
1.61
1.51
1.2
Basic Weighted Avg Shares
765
588
774
800
858
964
963
957
955
955
955
955
956
961
Sales/Revenue/Turnover
411
526
627
662
1,208
1,806
1,664
2,003
2,072
2,001
1,279
1,202
1,307
1,053
Operating Margin (%)
12.57
13.56
14.14
4.67
9.89
13.64
13.06
12.37
12.04
14.14
-2.06
-10.66
-3.8
-19.57
Depreciation Expense
21
39
48
82
91
112
120
124
131
136
138
140
146
- -
Net Income, GAAP
44
51
61
16
73
161
82
161
182
203
-82
-258
-160
-419
Effective Tax Rate (%)
10.51
11.35
13.08
- -
4.22
10.3
7.43
7.33
10.58
10.21
- -
- -
- -
- -
Profit Margin (%)
10.69
9.6
9.76
2.45
6.06
8.9
4.91
8.04
8.78
10.14
-6.43
-21.44
-12.2
-39.81
Working Capital
216
-73
-117
-32
619
293
191
345
458
584
188
-28
-222
-418
LT Debt
- -
100
110
30
109
140
61
251
243
238
144
236
190
295
Total Equity
636
709
756
1,052
1,952
2,079
2,078
2,164
2,288
2,510
2,428
2,144
1,986
1,666
Return on Invested Capital (%)
6.12
5.72
5.28
- -
3.59
7.04
5.3
6.13
6.18
6.97
- -
- -
- -
- -
Return on Capital (%)
7.01
6.67
6.63
- -
4.47
6.03
3.27
6
6.39
6.76
- -
- -
- -
- -
Return on Common Equity (%)
6.99
7.71
8.78
1.87
5.01
8.24
4.12
8.01
8.61
8.9
-3.53
-12.04
-8.21
-23.4

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,253
1,193
1,102
LT Borrowings
198
220
278
LT Finance Leases
20
18
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
963
963
963
Market Capitalization
6,088
4,306
4,739

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,568
1,404
1,254
Cash, Cash Equivalents & STI
516
479
354
Accounts Receivable, Net
389
356
295
Inventories
411
332
382
Total Current Liabilities
1,845
1,793
1,673
Payables & Accruals
- -
- -
- -
ST Debt
1,253
1,193
1,102
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.84%
-1.38%
-7.34%
Free Cash Flow
-339.96%
-81.1%
-323.15%
Net Income, GAAP
50.46%
11.81%
-38.1%
Sales/Revenue/Turnover
11.67%
-6.67%
8.73%
Total Cash Common Dividend
18.52%
-1.08%
-50.53%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
220
369
351
262
1,202
2025
316
346
- -
311
1,307
2026
304
293
145
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.01
- -
-0.21
-0.27
2025
-0.01
- -
- -
-0.16
-0.17
2026
-0.06
-0.11
-0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.06
0.09
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Tong Cai
Full Time Employees
1,195
Sector
Health technology
Industry
Pharmaceuticals: other
Address
18 Dongfang East Road Taicang JS China 215433
IPO Date
Aug 26, 2011
Business
ABA Chemicals Corporation (300261.SZ), founded in July 2003 and headquartered in Taicang, Jiangsu Province, China, engages in the research, development, production, and sale of fine chemicals, primarily serving the pharmaceutical, agrochemical, and nutritional health industries through its CDMO services and branded products. The company offers a broad portfolio of plant protection products including advanced pesticide intermediates, original drugs, preparations, plant growth regulators, herbicides, insecticides, and bactericides; pharmaceutical products encompassing intermediates, active pharmaceutical ingredients such as Levetiracetam, unnatural amino acids, pyrazoles, triazoles, azaindoles, indoles, aza-indoles, azetidines, and key intermediates like 6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane for Boceprevir and 2-chloro-1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-ethanone for Nebivolol; and nutritional health products such as NMN and AKG targeted at elderly, women, and children segments, distributed via e-commerce platforms including Tmall, Pinduoduo, JD, and Little Red Book. ABA operates seven production bases across China in locations including Taicang, Nantong Rudong, Yancheng Binhai, Xiangyang, Lanzhou, and Shangyu, plus a European base in Malta; three R&D centers anchored by Shanghai Zhangjiang Innovation Center (over 6,000 square meters), Puyi Chemical, and Yihui Biology; and maintains strategic partnerships with multinational firms such as Corteva (Kodiva), Bayer, Formis, Roche, Adimab (Aberdeen), Novartis, Teva, Daiichi Sankyo, and Sumitomo Chemical. Restructured as a joint stock limited company in February 2010 and listed on the Shenzhen Stock Exchange Growth Enterprise Market in September 2011 with registered capital of 963 million yuan, the company holds 132 domestic patents (66 invention patents) and 7 international patents, emphasizing chiral chemistry, heterocyclic chemistry, biocatalysis, continuous flow technology, and sustainable ESG practices validated by SBTi targets and Wind China Listed Companies ESG Top 100 inclusion. Recent developments include the August 2025 strategic partnership with Hengrui Pharma to advance pharmaceutical supply chain innovation and mutual growth; completion of the Yancheng Binhai South Area production facility in December 2024; trial production launch of a 2,000-ton chlorantraniliprole technical project; opening of a new R&D building in October 2024; ESG rating upgrade from BBB to AA by Wind in July 2025 (ranking 17th among 517 chemical peers and 4th in pesticides); establishment of a Lanzhou CPC branch and C93 workshop pilot in September and October 2025; and termination of certain Nantong projects and Gansu Haotian investment in 2024-2025 to realign with its customer-centric "2+X" strategy.